Board summary
Key figures
53,191
Registered population
61.0% aged 18–64
16.9%
Aged 65+
ICB 19.0% · England 17.9%
4.0%
Ethnic minority (non-White)
1.1% Asian · England 9.6%
68.3%
In IMD quintile 1
ICB 31.9% · England 21.0%
~37,004
Core20 residents (est.)
Resident basis; registered basis ~36,425 · see page 3
7,986
Hypertension register
+4.24% in 3 yrs · England +5.60%
563
SMI register
28.7% of Knowsley (LAD)'s
2,116
COPD register
Reviews +0.76% in 3 yrs
Forecast to 2030
9,131
Hypertension patients, 2030
+1,145 on today
67.3%
QRISK ≥20% on statins, 2030
+1.27pp over 3 yrs
4.3%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Wide practice variation in easy phone contact.
Easy phone contact spans 37.6 pp, from 26.4% at Dr Maassarani & Partners to 64.0% at The Macmillan Surgery, which may reflect triage demand.
Asthma annual review coverage trails comparators.
At 60.1% versus 62.9% in Knowsley and 65.7% in England, about 1,400 of 3,604 asthma patients (1,439) lack a recorded annual review.
Mental health BMI recording rose faster than England.
Annual BMI recording on the mental health register rose +16.2 pp over three years (England +5.1 pp), reaching 88.9% against 82.1% nationally.
Population, age and ethnicity
Children comprise 22.1% of Kirkby's 53,191 patients, exceeding national and borough benchmarks
Kirkby PCN registers 53,191 patients. Children aged 0–17 account for 22.1% (11,751 patients), above Knowsley (21.1%), the ICB (19.2%) and England (19.6%). Patients aged 65+ represent 16.9% (8,982 patients), matching Knowsley (16.9%) but below the ICB (19.0%) and England (17.9%). Associated Census usual residents are 96.0% White (Knowsley 95.3%, ICB 93.0%, England 81.1%), with 4.0% ethnic minorities; Census resident figures do not measure registered patients. Projected list growth of 3.8% to 2030 (Knowsley 2.8%, ICB 2.3%, England 2.3%) relies on an unverified methodology.
Age profile
65+: ICB 19.0%, England 17.9%
Ethnicity
Older people · falls rows are Knowsley (LAD) local-authority (LA) data, not PCN
| Measure | Local | North West | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Knowsley LA) | 2,784 | 2,071 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 82.8% | 82.9% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 53.6% | 56.6% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Knowsley LA) | 1,440 | 1,021 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Knowsley LA) | 23.1 | 18.2 | 14.8 | 2022‑24 |
Deprivation and Core20
Core20 patients comprise 68.3% of the list, peaking at Wingate Medical Centre's 76.7%
At 68.3%, the PCN Core20 cohort is higher than Knowsley (52.5%), the ICB (31.9%) and England (21.0%), with an average IMD decile of 2.5 (England 5.5). Resident estimates identify 37,004 people in deciles 1 and 2, while practice estimates sum to 36,425 patients. Concentration is highest at Wingate Medical Centre (76.7%), while estimated volume peaks at Dr Maassarani & Partners with 9,375 Core20 patients. Balancing outreach may require distinguishing high-concentration practices from large lists where patient volume could drive demand.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
563
SMI register
1.05% recorded prevalence
381
Learning disability register
0.71% recorded prevalence
8
Care homes, 177 beds
In the PCN catchment
11.5%
Provide unpaid care
Knowsley (LAD), Census 2021
Kirkby PCN records 563 patients on the severe mental illness register (1.1% prevalence vs Knowsley 1.2%, ICB 1.1%, England 1.0%) and 381 on the learning disability register (0.7% vs Knowsley 0.7%, ICB 0.6%, England 0.6%). Catchment services include 8 care homes with 177 beds (sites do not establish resident occupancy). Borough-level context for Knowsley recorded 14 people sleeping rough in the 2025 autumn snapshot.
Severe mental illness: physical health checks
Severe mental illness prevalence is 1.1%. Recorded BMI checks reach 88.9% (England 82.1%), but blood pressure checks (82.8%) trail England (83.4%), falling to 77.2% at Wingate Medical Centre. Prioritising blood pressure reviews could close physical health monitoring disparities.
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
7,986
Hypertension register
+4.24%
Register growth, 3 yrs
Knowsley (LAD) +5.44% · England +5.60%
+2.67pp
BP control, under 80
≤140/90 · −0.69pp aged 80+
+1,145
More patients by 2030
Forecast 9,131 (16.23%)
Hypertension case-finding and control
Hypertension prevalence is 14.9% (7,986 patients), trailing Knowsley (16.7%), the ICB (16.8%) and England (15.2%), with three-year register growth of +4.2% behind England (+5.6%). Unadjusted models indicate a benchmark gap of +115 to +899 patients, though these figures are not age-adjusted. For patients aged 80 and over, blood pressure control is 79.8% (England 81.2%) following a three-year change of -0.9% (England +2.2%). Lagging register expansion and declining blood pressure control in patients aged 80 and over suggest older cohorts may be underserved, making recall audits and case-finding operational priorities.
Lipids and statins
Among patients with QRISK ≥ 20%, 64.7% receive lipid-lowering therapy (England 63.6%), but three-year uptake grew +2.0%, trailing England (+6.2%). In diabetes without frailty, HbA1c control sits at 53.6% (England 57.4%). Slower initiation growth relative to England suggests primary prevention uptake is decelerating, highlighting an opportunity to prioritise cardiovascular risk reviews.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 115,615 | £1.60 | £1.71 | £1.86 | £184,984 |
| Cardiovascular (all), 2025 | 164,877 | £4.09 | £4.37 | £3.33 | £674,347 |
In 2026, the PCN prescribed 115,615 lipid-modifying drug items at £1.60 per item, compared with £1.63 in Knowsley, £1.71 in the ICB and £1.86 in England, spending £30,060 less than at England's unit cost. Lower unit costs relative to comparators mean the PCN can focus prescribing review capacity on patient adherence and optimal therapy rather than cost reduction.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
−0.06%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
−1.22%
Asthma prevalence, PCN 3-yr % change
Recorded respiratory prevalence is high: COPD is 4.0% (2,116 patients) against 1.9% in England, and asthma is 7.2% (3,604 patients) against 6.6% in England, alongside 5-19 asthma prescribing of 3,494 per 1,000 (England 1,488). However, annual reviews trail England for both COPD (70.6% vs 76.4%) and asthma (60.1% vs 65.7%), leaving about 1,400 asthma patients (calculated 1,439) without a recorded review. Lagging review rates alongside high prevalence could reflect recall bottlenecks, indicating that structured register call-and-recall should be prioritized.
Cancer register and children's immunisation
Cancer prevalence matches England at 3.8% (2,007 patients). For childhood immunisations in Q1 2025/26, 6-in-1 coverage at 12 months is 77.8% (England 91.0%), and MMR1 at 24 months is 73.4% (England 88.3%), below the 95.0% target. At age 5, MMR2 reaches 73.9%, trailing same-cohort MMR1 (86.6%) by 12.7 pp. Dose-two drop-off could leave young children unprotected, so pre-school catch-up recall is an operational priority.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
55.5%
Cheshire and Merseyside ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~2,640
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Cheshire and Merseyside ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Lung | 40.4% | 33.8% | 11% | 2,354 |
| Breast | 87.1% | 85.4% | 11% | 2,083 |
| Prostate | 52.3% | 53.2% | 12% | 2,037 |
| Bowel | 44.9% | 47.0% | 16% | 1,674 |
| Skin cancer | 86.9% | 87.8% | 21% | 932 |
In 2022, 55.5% of cancers with a known stage in NHS Cheshire and Merseyside ICB (7,482 of 13,490) were diagnosed at stage 1 or 2 (England 55.3%), 19.5 pp below the 75.0% national ambition by 2028. Staged cases were 72.8% of 18,522 registered cancers (England 67.0%), requiring about 2,640 additional early diagnoses across the ICB. This wider-system ICB metric does not measure PCN performance. At PCN level, cervical screening coverage is 69.8% (England 66.8%) with a 3-year change of -2.0% (England -1.0%), while breast screening coverage is 60.6% (England 69.9%) with a 3-year change of +21.7% (England +8.4%). Screening shortfalls could hinder early diagnosis, indicating potential scope to strengthen recall.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
In provisional July 2026 figures, Liverpool University Hospitals NHS Foundation Trust met the 28-day faster diagnosis standard at 75.5% (standard 75.0%; ICB 77.2%, England 79.3%), while Mersey and West Lancashire Teaching Hospitals NHS Trust achieved 72.4%. On the 62-day referral to treatment standard (standard 85.0%), Liverpool University Hospitals reached 73.3% (ICB 76.2%, England 71.2%, Mersey and West Lancashire 78.0%). For diagnostic waits over 6 weeks, the trust recorded 4.4% for ultrasound and 6.4% for MRI, below England (19.6% and 21.4%). Provider 62-day delays reinforce the necessity of active PCN safety-netting for fast-track referrals.
| Pathways within standard (%) | Liverpool | Mersey and West Lancashire | Wrightington, Wigan and Leigh | Cheshire and Merseyside ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 75.47 | 72.39 | 82.80 | 77.25 | 79.32 |
| 31-day treatment (96%) | 90.51 | 95.46 | 89.04 | 95.71 | 92.50 |
| 62-day referral to treatment (85%) | 73.26 | 77.96 | 76.78 | 76.23 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Liverpool | Mersey and West Lancashire | Wrightington, Wigan and Leigh | England |
|---|---|---|---|---|
| MRI | 6.42 | 14.04 | 0.49 | 21.40 |
| CT | 0.71 | 13.08 | 7.78 | 9.92 |
| Echocardiography | 12.55 | 34.88 | 24.37 | 28.48 |
| Colonoscopy | 33.14 | 18.04 | 6.10 | 30.83 |
| Gastroscopy | 44.99 | 18.17 | 12.54 | 29.02 |
| All 15 DM01 tests | 11.50 | 21.17 | 14.36 | 23.14 |
| Community services activity | Knowsley residents | Cheshire and Merseyside ICB |
|---|---|---|
| Care contacts | 45,655 | 541,280 |
| Referrals | 8,475 | 97,150 |
| Patients with a contact | 12,490 | 146,240 |
Community services (residents of Knowsley), Jun 2026 (provisional). Provisional June 2026 Community Services Dataset records indicate that 57.9% of community contacts for Knowsley borough residents (26,435 of 45,655) were with adults aged 65 and over. These figures describe local authority resident activity rather than PCN-specific caseloads. High community contact concentration among older adults underscores opportunities to coordinate proactive chronic disease and cancer surveillance with community nursing teams.
Practice variation and patient experience
Practice phone access varies by 37.6 pp while overall satisfaction spans 28.2 pp
In 2025/26, clinical QOF achievement reached 100.0% at Millbrook Medical Centre, The Macmillan Surgery, and Wingate Medical Centre, but 92.1% at Dr Maassarani & Partners (England 97.1%). All five practices attained 15.6% in vaccination and immunisation against 55.2% nationally. High clinical points do not guarantee complete population reach across immunisation pathways.
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Millbrook | 104 | 63.5 | 62.4% | 69.9% | 86.7% |
| Macmillan | 122 | 74.2 | 64.0% | 77.1% | 83.6% |
| Wingate | 141 | 76.7 | 45.6% | 71.4% | 80.2% |
| St. Laurence's | 90 | 75.1 | 31.7% | 63.8% | 71.0% |
| Dr Maassarani & | 118 | 60.8 | 26.4% | 72.9% | 58.4% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Ten of 25 tracked measures trailed England's three-year change, led by learning disability
Across 25 tracked indicators, 10 measures trailed England's three-year change. The widest relative shortfalls against England were learning disability prevalence (-0.7% vs +5.4%), asthma reviews (-0.1% vs +4.4%), QRISK ≥ 20% lipid therapy (+2.0% vs +6.2%), and blood pressure control in patients aged 80 and over (-0.9% vs +2.2%). Conversely, notable gains outpaced England in mental health physical checks (alcohol recording +20.7 pp vs +5.4 pp; BMI recording +16.2 pp vs +5.1 pp) and breast screening coverage (+21.7% vs +8.4%).
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Learning disability register
Asthma reviews
QRISK statin treatment
BP control, 80+
COPD reviews
Alcohol record (psychosis)
Breast screening (53-70)
BMI record (SMI)
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Knowsley (LAD) | Asset | PCN | Knowsley (LAD) |
|---|---|---|---|---|---|
| Care homes (catchment) | 8 (177 beds) | n/a | Schools (catchment) | 44 | n/a |
| Children's centres | 5 | 15 | Places of worship | 21 | 48 |
| Libraries | 1 | 3 | Primary schools (LA maintained) | 15 | 32 |
| Primary academies | n/a | 13 | Special schools | 1 | 2 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Structured asthma annual review recall
Asthma review coverage is 60.1% (England 65.7%, Knowsley 62.9%) on a register of 3,604 patients (7.2% prevalence), leaving 1,439 (about 1,400) unreviewed. For discussion, the PCN could run structured call-and-recall searches and offer flexible or after-school review slots across high-volume and high-share practices. Moderate effort to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 2
Opportunistic hypertension case-finding and audit
Hypertension prevalence is 14.9% (7,986 of 53,191 patients) vs England (15.2%) and Knowsley (16.7%), giving an unadjusted gap of +115 to +899 patients. For discussion, practices could search clinical records for repeated raised blood pressure readings without a diagnosis code and offer opportunistic checks at routine contacts. Low cost, quick to run.
Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.
Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).
Option 3
Practice telephony and triage review
GP Patient Survey easy phone contact spans 37.6 pp across the 5 practices, from 26.4% at Dr Maassarani & Partners to 64.0% at The Macmillan Surgery (England 56.9%). For discussion, the PCN could audit peak call queues, drop-out rates and online triage pathways at lower-scoring practices to share booking workflows. Moderate effort to run.
Evidence base: patient-reported access and experience is the demand-side signal on primary-care capacity and access model; practices with sustained poor experience are the ones to prioritise for access-model support.
Policy anchor: 10 Year Health Plan, shift from hospital to community (Neighbourhood Health Service).
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Paediatric capacity and triage review (p2) | Aged 0-17 | Medium Term Planning Framework 2026 · Neighbourhood health framework | PCN |
| Two-track Core20 outreach (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| Severe mental illness health checks (p4) | SMI register with a BP check in the last 12 months | MHIS · From Harm to Hope | PCN |
| Hypertension case finding and recall (p5) | Last BP reading of patients (80+ yrs with hypertension) in the last 12 months is <= 150/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Childhood immunisation recall outreach (p6) | MMR dose 1 coverage at 24 months | 10YHP sickness to prevention · 95% target | PCN |
| Cervical screening recall audit (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | PCN |
| Telephony and triage capacity review (p9) | GPPS easy to contact the practice by phone | 10YHP, hospital to community | Practice |
| Option 1 · Structured asthma annual review recall (p12) | Asthma register · Asthma: QOF prevalence · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) | Core20PLUS5 respiratory | PCN |
| Option 2 · Opportunistic hypertension case-finding and audit (p12) | Hypertension register · Hypertension: QOF prevalence · Registered population | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Option 3 · Practice telephony and triage review (p12) | GPPS easy to contact the practice by phone · GPPS survey response rate | 10YHP, hospital to community | Practice |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | Local authority | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
